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Letter reSeArCH individually delete ten embryonic enhancers, each with strong evolutionary conservation and robust limb activity in transgenic mouse reporter assays [13] [14] [15] [16] [17] (VISTA Enhancer Browser: https://enhancer.lbl. gov/) ( Fig. 1a , Extended Data Fig. 1a -j and Supplementary Table 1 ). Each enhancer (identified by VISTA ID number) is located in the vicinity of a gene associated with human congenital limb malformations, and deletion of these genes in mice results in limb phenotypes ranging from polydactyly (Gli3) to complete loss of limbs (Fgf10) (Extended Data Fig. 1 and Supplementary Table 2 ). In all cases, the limb activity pattern of the enhancer at embryonic day 11.5 (E11.5) overlaps spatial RNA expression of the associated target gene, suggesting that these enhancers are part of the regulatory architecture that controls the expression of these genes [16] [17] [18] [19] [20] [21] (Extended Data Fig. 2 ). Capture-C chromatin conformation data from embryonic limbs 22 confirmed that at least six of these enhancers physically interacted with their predicted target genes (Extended Data Fig. 1k ). This framework enabled us to investigate the functional contribution of each enhancer by comparing the potential limb skeletal abnormalities caused by enhancer loss to the phenotypes observed in gene knockout mice.
Unexpectedly, we did not detect any abnormalities in bone number, shape, length, position or mineralization in mice in which any of the ten single enhancers was deleted ( Fig. 1b and Extended Data Fig. 3) . Similarly, we observed neither significant differences in predicted target gene expression in embryonic limbs for nine out of ten individual enhancer deletions, nor obvious changes in local H3K27ac (acetylation of lysine 27 on histone H3) signatures outside the deleted enhancers (Extended Data Figs 2, 4 ). Together, these results suggest that a substantial proportion of limb enhancers, even if highly conserved in evolution, are not individually essential for normal limb morphogenesis.
One possible explanation for the lack of an obvious phenotype in individual limb enhancer knockout lines is that different enhancers associated with the same gene may have spatiotemporally redundant, rather than unique, activity. Our selected panel of enhancers ( Fig. 1b and Extended Data Fig. 1a -j) included three enhancer pairs with overlapping limb activity domains and the same predicted target gene (mm1179-hs1586, hs741-hs1262, and hs1467-mm636; Extended Data Fig. 5a -c). Using iterative CRISPR-Cas9 genome editing, we generated double enhancer knockout (DKO) mice for each enhancer pair (Extended Data Fig. 5a-d, g, j) , such that both deletions occurred in cis. In two out of three cases, involving enhancer pairs near Gli3 and Shox2, homozygous DKO embryos showed phenotypic abnormalities affecting skeletal limb morphology ( Fig. 2a-d and Extended Data Fig. 5f , i, j). Mice lacking both enhancers near Gli3 (mm1179 and hs1586) had substantially reduced Gli3 expression in the embryonic hand plate and exhibited forelimb-specific polydactyly ( Fig. 2c and Extended Data Fig. 5e , f), a phenotypic hallmark of diminished Gli3 expression 23, 24 . In addition, combined deletion of the two enhancers near Shox2 (hs741 and hs1262) reduced Shox2 expression, predominantly in embryonic hindlimbs, and resulted in a marked reduction in femur ossification ( Fig. 2d and Extended Data Fig. 5h , i), consistent with the stylopod reductions observed when the Shox2 gene is inactivated 18, 25 . Together, these results show that although each of the four enhancers near Gli3 and Shox2 is individually dispensable for limb morphology, the respective pairs of enhancers are collectively required for normal limb development.
To examine the degree of overlap between the activity patterns of phenotypically redundant enhancers at the cellular level, we generated transgenic mouse lines expressing fluorescent reporters under the control of each of the Gli3 or Shox2 enhancers (mm1179-GFP, hs1586-mCherry, hs741-GFP and hs1262-mCherry). Using immunofluorescence on limb sections from double transgenic embryos, we tracked the activity of each of the four enhancers during limb development ( Fig. 2e , f and Extended Data Fig. 6 ). Consistent with the preaxial polydactyly observed in Gli3 DKO embryos, limb progenitor cells marked by both Gli3 enhancers were observed at high density in the anterior limb mesenchyme ( Fig. 2e and Extended Data Fig. 6c, d ). In Shox2 double enhancer reporter embryos, a major accumulation of cells with dual Shox2 enhancer activities is present in a proximal limb mesenchymal cell population known to harbour stylopod progenitors 12 (Fig. 2f ). In conjunction with our deletion studies, these results illustrate the degree of functional overlap between pairs of enhancers near the same gene at the cellular level.
Considering the apparent contrast between the morphological redundancy of pairs of enhancers and the strong evolutionary conservation of each individual enhancer, we studied the phenotypic effect of single and combinatorial enhancer deletions in sensitized genetic backgrounds carrying heterozygous deletions of the presumptive target genes ( Fig. 3 ). We used CRISPR-Cas9 to engineer Gli3 and Shox2 gene loss-of-function alleles, which recapitulated expected gene dosage reductions and previously published phenotypes (Extended Data Figs 7, 8) . We then used these alleles to generate compound heterozygous mice harbouring one or more disrupted enhancers with a wildtype gene on one allele and a disrupted gene but wild-type enhancers on the other allele ( Fig. 3 ). For Gli3, the absence of either enhancer (mm1179 or hs1586) in the presence of only one functional Gli3 allele resulted in a supernumerary anterior digit ( Fig. 3a and Extended Data Fig. 8a ), which is more severe than the terminally bifurcated thumb observed in Gli3 heterozygotes ( Fig. 3a) . Similarly, for Shox2 the removal of either neighbouring enhancer (hs1262 or hs741) in combination with compound heterozygous deletion of the Shox2 gene resulted in a more pronounced reduction in femur length than observed in Shox2 heterozygotes ( Fig. 3b ). For both pairs of enhancers, compound heterozygous mice carrying deletions of both enhancers on one allele and a deletion of the gene on the other allele showed even more severe phenotypes. In the case of Gli3, loss of both enhancers over a Gli3 null allele resulted in greatly reduced expression of Gli3 (Extended Data Fig. 7b , c) and severe pre-axial polydactyly in forelimbs, similar in severity to homozygous loss of the Gli3 gene 24 ( Fig. 3a and Extended Data Fig. 8a ). Likewise, compound heterozygous deletion of enhancers hs741 and hs1262 over a Shox2 gene deletion strongly reduced Shox2 expression (Extended Data Fig. 7e , f) and resulted in a severe reduction in femur length and substantial shortening of the humerus ( Fig. 3b and Extended Data Fig. 8b , c), consistent with the phenotypes that result from homozygous Shox2 gene loss 18, 25 . Together, our data demonstrate that these developmental enhancers, although seemingly dispensable under non-sensitized conditions, show individual functional contributions to limb development under conditions of reduced genetic robustness.
The lack of phenotypic change upon deletion of individual enhancers, and the functional redundancy observed among enhancer pairs, raises the question of how commonly such redundancy occurs in mammalian gene regulatory landscapes. To explore this question systematically, we devised a genome-wide, correlation-based computational approach to estimate the number of enhancers that regulate each gene Letter reSeArCH during development, taking advantage of chromatin signatures of distal enhancers and gene transcription measured across multiple tissues and time points of mouse development ( Fig. 4 and Extended Data Figs 9, 10). We analysed correlations between H3K27ac chromatin immunoprecipitation followed by sequencing (ChIP-seq) and RNA sequencing (RNA-seq) datasets from twelve different mouse tissues at two or three embryonic or perinatal time points per tissue (https://www.encode project.org/) to assign each enhancer to its most likely target gene within the same topologically associated domain (TAD) 26 (Fig. 4 , Extended Data Fig. 9a -c and Methods). We then used this framework to examine the average number of enhancers associated with genes expressed in three developmental tissues (limb, heart, and forebrain). Genes with limb-biased expression showed a median of three associated distal enhancers, versus a median of zero for housekeeping genes (Extended Data Fig. 9d, e ). For the specific class of limb-biased genes encoding transcription factors, we observed an even more complex enhancer landscape, with a median of eight distinct enhancers per gene ( Fig. 4b) . Notably, some of these transcription factor genes were associated with more than ten tissue-specific limb enhancers with highly overlapping activity patterns in the same tissue (Fig. 4c, d and Methods). We observed similarly large numbers of potentially redundant enhancers near brain-and heart-specific transcription factor genes (Extended Data Fig. 10a, b ). Even under stringent correlation thresholds, our analysis uncovered 1,058 genes associated with five or more enhancers showing putatively redundant activity patternsthat is, enhancers that are active in the same tissue (Extended Data Fig. 10c-f ). These results indicate that developmentally expressed genes are commonly associated with multiple enhancers that show overlapping activity patterns, supporting the widespread existence of functionally redundant enhancers in mammalian genomes.
Studies of individual loci have identified examples of mammalian enhancers near the same gene with remarkably similar spatiotemporal activity patterns or functions 15, [27] [28] [29] [30] [31] [32] , reminiscent of invertebrate 'shadow enhancers' 8, 9, [33] [34] [35] . The lack of marked morphological phenotypes in our enhancer deletion mouse models suggests that panels of mammalian enhancers with large degrees of redundancy act as a regulatory buffer for key developmental processes, thereby reducing the likelihood of severe consequences resulting from genetic or environmental challenges 8 . Although individual examples of enhancers whose loss leads to severe phenotypes have been described 4, 36 , our findings suggest that redundancy is far more common. As indicated by the phenotypes observed in sensitized genetic backgrounds, our results suggest that pairs of enhancers act redundantly in organismal patterning, but additively in establishing gene expression levels. This observation is consistent with high-throughput loss-of-function screens in cultured cells, in which the disruption of individual enhancers leads to measurable gene expression changes but rarely results in the complete loss of target gene expression 37 . It appears plausible to assume that limited but specific contributions to overall gene expression levels are relevant for organismal fitness under specific pressures, thus subjecting enhancers to purifying selection over evolutionary time. Alternatively, additional tissue-specific functions may also explain the evolutionary constraints on these loci.
Our observations have implications for the interpretation of noncoding regulatory variants in relation to human phenotypes. Our findings suggest that many loss-of-function enhancer mutations will cause, at most, subtle phenotypes in humans. Thus, for many genetic loci, enhancer-associated disease phenotypes may be more likely to result from gain-of-function mutations that either expand enhancer activity 38 or alter the positions of enhancers relative to genes 39 .
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MethODS Experimental design. All animal work was reviewed and approved by the Lawrence Berkeley National Laboratory (LBNL) Animal Welfare Committee. All mice used in this study were housed at the Animal Care Facility (ACF) at LBNL. Mice were monitored daily for food and water intake, and animals were inspected weekly by the Chair of the Animal Welfare and Research Committee and the head of the animal facility in consultation with the veterinary staff. The LBNL ACF is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC). Transgenic mouse assays and enhancer knockouts were performed in Mus musculus FVB strain mice. The following developmental stages were used in this study: embryonic day E10.5, E11.5, E12.5 and E18.5 mice. Animals of both sexes were used in the analysis. Sample size selection and randomization strategies were conducted as described below. Transgenic mouse assay selection and randomization. Sample sizes were selected empirically on the basis of our previous experience of performing transgenic mouse assays for more than 2,000 total putative enhancers (VISTA Enhancer Browser: https://enhancer.lbl.gov/). Mouse embryos were excluded from further analysis if they did not contain the reporter transgene or if the developmental stage was not correct. All transgenic mice were treated with identical experimental conditions. Randomization and experimenter blinding were unnecessary and not performed. Enhancer knockout selection and randomization. Sample sizes were selected empirically on the basis of our previous studies 15 . All phenotypic characterization of knockout mice used a matched littermate selection strategy. All phenotyped mice described in the paper resulted from crossing heterozygous enhancer deletion mice together to allow the comparison of matched littermates of different genotypes. Embryonic samples used for in situ hybridizations, RNA-seq, and skeletal preparations were dissected blinded to genotype. In vivo transgenic reporter assays. Enhancer names in this study are the unique identifiers used in the VISTA Enhancer Browser (https://enhancer.lbl.gov/; mm: originally identified in mouse; hs: originally identified in human). Transgenic results for most enhancers have been reported previously [13] [14] [15] [16] . Newly tested enhancers (hs1586 at E10.5 and hs1262) were amplified from human genomic DNA and cloned into an hsp68-lacZ expression vector as previously described 14 .
Genomic coordinates of all enhancers are listed in Supplementary Table 1 . LacZ transgenic mouse assays were conducted as previously described 14, 40 . To directly compare the activity domains between apparently redundant enhancers, enhancers were cloned, using Gateway (Thermo Fisher Scientific) or Gibson 41 methods, into an hsp68-based reporter vector similar to that described above, with the exception of a fluorescent reporter replacing LacZ. The enhancer-reporter combinations were generated as follows: mm1179-sfGFP, hs1586-mCherry, hs741-sfGFP and hs1262-mCherry. sfGFP is a fusion of Sun1 and 2× sfGFP as described 42 and localizes to the nuclear membrane. Mice carrying the individual fluorescent reporter transgenes were then generated via pronuclear injection (using FVB strain zygotes), and stable lines were established from founders showing reproducible reporter activity in the embryonic limb. Generation of enhancer knockout mice using CRISPR-Cas9. Mouse strains lacking limb enhancer(s) or harbouring gene loss-of-function alleles were generated using in vivo CRISPR-Cas9 editing, as previously described, with only minor modifications 43, 44 . Pairs of single guide RNAs (sgRNAs) targeting genomic sequence 5′ and 3′ to the sequence to be deleted were designed using CHOPCHOP 45 (see Supplementary Table 1 for sgRNA sequences and coordinates of deleted regions). Knockout mice were engineered as described previously 46 using a mix containing Cas9 mRNA (final concentration of 100 ng/μ l) and two sgRNAs (25 ng/μ l each) in injection buffer (10 mM Tris, pH 7.5; 0.1 mM EDTA). This mix was injected into the cytoplasm of single-cell FVB strain mouse embryos. Founder (F0) mice were genotyped using PCR with High Fidelity Platinum Taq Polymerase (Thermo Fisher Scientific) to identify those with the desired non-homologous end joining (NHEJ)-generated deletion breakpoints (see Extended Data Figs 1a-j, 5a-c, 7a, d and Supplementary Table 3 for genotyping strategy, primer sequences and PCR amplicons). Sanger sequencing was used to identify and confirm deletion breakpoints in F0 and F1 mice (Extended Data Figs 1a-j, 5a-c, 7a, d). Unless noted otherwise, mice homozygous-null for the targeted limb enhancers showed normal pre-and postnatal viability and appeared outwardly normal. For iterative CRISPR-Cas9 genome editing, fertilized mouse eggs harbouring the primary deletion were collected and injected with sgRNAs targeting the secondary enhancer for deletion. Only those founder lines harbouring both deletions on the same haplotype were analysed further. In situ hybridization and skeletal preparations. To assess spatial changes in gene expression in mouse embryonic limbs, whole mount in situ hybridization using digoxigenin-labelled antisense riboprobes was carried out as previously described 46 . Forelimbs and hindlimbs from at least three independent embryos were analysed for each genotype (including wild-type littermate controls). Mouse embryonic skeletons at E18.5 were stained with Alcian blue and Alizarin red to differentiate cartilage (blue) and bone (red) using standard methods 47 . For comparison of limb skeletons from enhancer knockout embryos and wild-type littermates, general parameters such as bone number, shape, length, position or mineralization were assessed. Embryonic limbs and limb skeletons were imaged, and skeletal elements were measured, using a Leica MZ16 stereo-microscope coupled to a Leica DFC300Fx or DFC420 digital camera. Brightness and contrast were adjusted uniformly using Photoshop CS5. Measurements of the ossified portions of humerus and femur (stylopodial elements) were normalized to those of the ulna and tibia (related zeugopodial elements), respectively (as shown in Figs 2d, 3b and Extended Data Figs 5i, 8c) . Quantitative real-time PCR (qPCR) and RNA-seq. RNA was isolated from microdissected forelimbs or hindlimbs of mouse embryos at E11.5 using the Ambion RNAqueous Total RNA Isolation Kit (Life Technologies) according to the manufacturer's instructions. For qPCR, RNA was treated with RNase-free DNase (Promega) and reverse transcribed using SuperScript III (Life Technologies) with random hexamer or poly-dT priming according to the manufacturer's instructions. qPCR was performed on a LightCycler 480 (Roche) using KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems) according to the manufacturer's instructions. qPCR primers (listed in Supplementary Table 4 ) were designed in silico using Primer3 (http://primer3.wi.mit.edu/), and amplicons span exon-exon junctions in order to prevent amplification of genomic DNA. Relative gene expression levels were calculated using the 2 −ΔΔC t method 48 , normalized to the Actb housekeeping gene, and the mean of wild-type control samples was set to 1.
For RNA-seq, RNA samples were treated with DNase (TURBO DNA-free Kit, Life Technologies), and RNA quality was verified using a 2100 Bioanalyzer (Agilent) with an RNA 6000 Nano Kit (Agilent). RNA-seq libraries were generated using the TruSeq Stranded mRNA Sample Prep Kit (Illumina), following the manufacturer's instructions, and purified, eluted, and quantified as described previously 49 . RNA-seq libraries were pooled (four per lane) and sequenced using single end 50-bp reads on a HiSeq 4000 (Illumina). Immunofluorescence. Mouse embryonic limbs at E10.5, E11.5 or E12.5 were dissected in cold PBS and fixed in 4% PFA for 2-3 h. Following incubation in a sucrose gradient and embedding in a 1:1 mixture of 30% sucrose and optimum cutting temperature solution, sagittal 10-μ m frozen sections were cut using a cryostat. Cryosections were incubated overnight with the following primary antibodies: chicken anti-GFP (1:500, Thermo Fisher Scientific, A10262), rabbit anti-mCherry (1:1,000, Thermo Fisher Scientific, PA5-34974) and goat anti-Sox9 (1:500, R&D Systems, AF3075). Goat-anti chicken, goat anti-rabbit and donkey anti-goat secondary antibodies conjugated to Alexa Fluor 488, 568, 594 or 647 (1:1,000, Thermo Fisher Scientific) were used for detection. Hoechst 33258 (Sigma-Aldrich) was used to counterstain nuclei. Fluorescent images were acquired using a Zeiss AxioImager fluorescence microscope in combination with a Hamamatsu Orca-03 camera. Brightness and contrast were adjusted uniformly using Photoshop CS5. ChIP-seq. For each of six single enhancer knockout lines, ChIP-seq to H3K27ac was performed using a protocol optimized for mouse embryonic tissues 50 . In brief, forelimb buds from ten wild-type embryos (four biological replicates) and ten enhancer knockout embryos (at least two biological replicates) were dissected at E11.5, formaldehyde crosslinked, and sheared using a Diagenode Bioruptor Sonicator. After pre-clearing, chromatin was incubated with anti-H3K27ac antibody (Active Motif cat no. 39133) for 2 h at 4 °C. Freshly rinsed Dynabeads (1:1 protein A:protein G mix) were then added to the antibody-treated chromatin, and immunoprecipitation was performed on a rotator for 30 min at 4 °C. Libraries were prepared using the Illumina Truseq DNA sample prep kit following the manufacturer's instructions with minor modifications. Library quality was assessed using a 2100 Bioanalyzer with the High Sensitivity DNA Kit (Agilent), and quantification was performed using a Qubit Fluorometer with the dsDNA HS Assay Kit (Life Technologies). ChIP-seq and input libraries were pooled and sequenced via single-end 50-bp reads on a HiSeq 2000 or 4000 (Illumina). RNA-seq and ChIP-seq analysis. Analysis of ChIP-seq and RNA-seq data from limb enhancer knockout and related wild-type control samples was performed as follows: CASAVA v1.8.0 (Illumina) was used to demultiplex data, and reads with CASAVA 'Y' flag (purity filtering) were discarded. For each sample, between 12 million and 55 million (ChIP-seq) or 23 million and 71 million (RNA-seq) reads were obtained following quality filtering and adaptor trimming using cutadapt_v1.1 (https://cutadapt.readthedocs.io/) with parameter '-m 25 -q 25' . Mouse genome sequence (mm9) and gene annotations were retrieved from the iGenomes repository (https://support.illumina.com/sequencing/sequencing_ software/igenome.html).
To align the RNA-seq reads to the mouse reference genome and transcriptome, we used Tophat v2.0.6 51 , and the reads mapping to UCSC known genes were counted by HTSeq 52 . Genes with counts per million (CPM) > 1 in at least two samples were processed for further differential gene expression analysis comparing enhancer knockout and wild-type control samples using edgeR 53 . In each case, the Letter reSeArCH top 100 differentially expressed genes, sorted by false discovery rate (FDR), are listed in Supplementary Tables 5-7 .
For read mapping and peak calling of ChIP-seq datasets, bowtie 54 (version 0.12.8) with parameter '-m 1 -v 2' and MACS 55 (version 1.4.2) with parameter '-mfold = 10,30 -nomodel -p 0.0001' were used, respectively. Biological replicates were combined using MSPC 56 , with the following parameters: -r biological -s 1E-10 -W 1E-6 -m Highest -c 2. The predicted enhancer intervals were assigned the best P value (as defined by MACS 55 ) among the overlapping peaks. ENCODE ChIP-seq data analysis. Raw data were downloaded from the Data Coordination Center of the ENCODE project (https://www.encodeproject.org/, see Supplementary Table 8 for the complete list of sample identifiers). Short reads were aligned to the mm10 assembly of the mouse genome using bowtie 54 , with the following parameters: -a -m 1 -n 2 -l 32 -e 3001. Peak calling was performed using MACS v1.4 55 , with the following arguments: -gsize = mm-bw = 300-nomodel-shiftsize = 100. Experiment-matched input DNA was used as a control. ENCODE RNA-seq data analysis. Raw data were downloaded from the ENCODE Data Coordination Center (https://www.encodeproject.org/, see Supplementary Table 8 for the complete list of sample identifiers). Short reads were aligned to the mm10 assembly of the mouse genome using Tophat v2.0.8 57 and Gencode vM3 58 as the reference transcriptome. Cuffnorm v2.2.1 51 was run to quantify transcripts across conditions using the Gencode vM3 58 transcriptome as the reference and setting -library-norm-method to geometric. Only genes with a level of expression of at least one RPKM (reads per kilobase of exons per million mapped reads) in at least one of the considered conditions were included in further analyses. Small and non-coding RNAs were excluded by retaining only those genes with a Gencode biotype 58 supporting protein-coding functionality. Classifying genes by tissue-biased patterns of expression. For each proteincoding gene in the mouse genome, the expression variability across the twenty-nine ENCODE RNA-seq experiments from multiple tissues and developmental time points was evaluated using two metrics: a measure of tissue-specificity (τ) 59 ranging from 0 (consistent expression across all conditions) to 1 (expression in one single condition); and a measure of relative expression in a condition of interest (for example, limb at E11.5). Given a gene, the latter was defined as the difference between the percentile of expression of the gene in the given condition and the median percentile of expression across all the samples. A large positive number indicates a gene that is much more expressed in the condition of interest than the average.
Tissue-biased genes were defined as showing τ ≥ 0.7 and relative expression higher than the 95th percentile. Housekeeping genes were defined as having τ ≤ 0.4 and relative expression between the 5th and 95th percentiles. The complete lists of genes assigned to each category are available in Supplementary Table 9 . Gene classification based on pre-specified functional categories. Tissue-biased developmental transcription factors (sometimes referred to as tissue-specific transcription factors) were defined as genes with biased expression in a given tissue (see previous section), associated with abnormal developmental phenotypes in the same tissue (terms extracted from the Mouse Genome Informatics (MGI) database 60 , listed in Supplementary Table 10 ) and annotated as a transcription factor under the terms GO:0003700 or GO:0003705 in the Gene Ontology (GO) 61 . Annotations were downloaded from GO and MGI on July 7, 2016. Topologically associated domains. TAD coordinates 26 estimated from mouse embryonic stem cell Hi-C data were downloaded from http://chromosome.sdsc. edu/mouse/hi-c/download.html. Coordinates were converted from mm9 to mm10 using liftOver 62 . A statistical framework defining enhancer-promoter associations genomewide. A list of putative enhancer regions was first defined as follows: after excluding any region annotated to the mitochondrial or any random chromosome, the BED coordinates of the H3K27ac peaks across the twenty-nine conditions (different combinations of tissue and developmental stage as defined by the ENCODE consortium, see 'ENCODE ChIP-seq data analysis' above) were merged using the mergeBed utility from BEDTools v.2.17.0 63 . For a more robust signal estimation (see below), regions shorter than 500 bp were enlarged to 1 kb from their central coordinate. Promoters, defined as regions within 2.5 kb of the transcriptional start sites of genes annotated in Gencode vM3 58 , were then excluded using subtractBed from BEDTools v.2.17.0 63 . After that, any remaining region shorter than 1 kb was excluded. Uniquely aligned, de-duplicated reads were then used to quantify the H3K27ac signals at each region, for each one of the 29 conditions. These signals were measured using the coverageBed utility from BEDTools v.2.17.0 63 , normalized to RPKM (according to the sequencing depth of each specific sample), and log 2 -transformed. The resulting list of 74,366 predicted enhancers and their corresponding H3K27ac signal quantifications, along with the mRNA expression measurements for the protein-coding genes (as defined in 'Classifying genes by tissue-biased patterns of expression'), were used as input for the statistical framework described below. The main steps of the approach are also outlined in Extended Data Fig. 9b .
For each previously defined TAD in the mouse genome 26 , we retrieved all of the enhancers predicted and the genes expressed in at least one of the twenty-nine conditions considered that fell within that TAD. Pairwise correlations between all possible enhancer-gene combinations within the TAD were then evaluated by calculating Spearman's rank correlation coefficient (SCC) between the H3K27ac pattern of enrichment at the enhancer and the mRNA expression of the gene across the conditions. Each putative enhancer was initially assigned to the gene showing the highest SCC value (in the very rare case of ties, all of the genes showing the same SCC value were assigned to the enhancer). After that, a null distribution of SCC values was estimated empirically, by pairing the enhancer with 1,000 randomly picked genes from the same chromosome. The z-score for the correlation coefficient was then calculated by subtracting the mean and dividing by the standard deviation estimated from the empirical null. The corresponding P value was calculated using the pnorm function in R. Finally, only those putative enhancers showing a P value ≤ 0.05 and a SCC > = 0.25 were retained, resulting in a set of 34,882 enhancers with an assigned target ( Supplementary  Table 11 ). Considering the entire, genome-wide set of pairwise associations, a P = 0.05 corresponds to a Benjamini-Hochberg corrected FDR of 0.087. This analysis resulted in the assignment of one or more putative enhancers to 9,365 protein-coding genes ( Supplementary Table 12 ). To define a set of genes with many redundant enhancers, we considered enhancers as redundant only if they were associated with the same gene by correlation and showed a strong peak of H3K27ac in the same exact tissue under examination (for example, both enhancers are active in limb and linked to the Gli3 gene). Although this correlative approach may result in a subset of false-positive assignments for individual genes, it enables an approximation of both regulatory complexity and potential enhancer redundancy across the entire genome. We found 1,276 genes that showed multiple assigned enhancers such that at least five of the enhancers were all active in the same tissue (limb, heart or brain). We then used a permutation scheme to directly evaluate the statistical robustness of this conclusion (that is, 1,276 genes with 5 or more redundant enhancers in either developing limbs, heart or forebrain), which considered increasingly higher correlation values between the activity of putative enhancers and expression of genes (Extended Data Fig. 10c-f) . By re-shuffling the expression values of each gene across conditions (100 genome-wide permutations), we estimated the FDR of observing a gene with five or more enhancers attached to it, for increasingly larger correlation coefficients. Each permutation consisted of the same enhancers and genes, in which the H3K27ac values were left as in the actual data whereas the RNA expression values of the genes across the different samples were randomly reshuffled. For each genome-wide permuted matrix, the entire statistical approach described above was re-run and a map of enhancer-promoter associations was generated. For each value of Spearman's correlation coefficient (0.25 to 0.75, with a 0.01 step) the number of genes showing five or more enhancers in the permuted data was calculated. The average across the 100 iterations was then computed and used for FDR estimation. This was calculated as the average number of genes showing five or more enhancers across the permuted data, over the number of genes derived from the actual data. Statistical analysis. Statistical analyses are described in detail in the Methods sections above. Whenever a P value is reported in the text, the statistical test is also indicated. Unless specified otherwise, all the statistics were estimated and plots drawn using the statistical computing environment R (https://www.r-project.org) or GraphPad Prism 7 software. Data availability. ChIP-seq and RNA-seq datasets are available in the NCBI GEO database with the accession code GSE93730. Additional data supporting the findings of this study are available from the corresponding authors upon reasonable request.
Extended Data Figure 1 | CRISPR deletion of ten limb enhancers and regulatory interaction landscape of associated target genes. a-j, Left, representative activity patterns of the selected enhancers in mouse embryos at E11.5 (VISTA enhancer browser) 13 and the respective genomic enhancer regions tested in transgenic assays (Tg, blue bar), along with the regions deleted in enhancer knockout mice (Del, red bar). Corresponding H3K27 acetylation patterns (green) in wild-type mouse embryonic forelimbs at E11.5 (this study) are depicted with open chromatin (ENCODE DHS in forelimbs at E11.5, purple) and the Placental Mammal basewise conservation track by PhyloP (Cons, blue/red). Scale bars, 500 bp. VISTA enhancer IDs (mm and hs numbers) are indicated on the left, with the distance of the enhancer from the transcriptional start site of the predicted target gene in the mouse genome. Numbers at the bottom right of each embryo indicate the reproducibility of the enhancer reporter assay. Arrowheads mark additional activity domains (other than limb): hs1262 (hindbrain, reproducibility: 5/6, also shown previously 17 ), mm917 (dorsal root ganglion, 7/7) and hs1603 (nose, 7/7; and branchial arch, 5/7). Asterisk indicates potential craniofacial enhancer activity for mm636, which was observed in 3 of 9 embryos 64 . Right, PCR validation strategy and results for enhancer knockout lines. Red scissors indicate CRISPR-mediated deletion breakpoints. PCR was used to detect the wild-type (+ ) and enhancer deletion (Δ ) alleles. Below, Sanger sequencing traces show the deletion breakpoints (indicated by the dashed line) for the enhancer knockout alleles. PCR genotyping results are shown with amplicon sizes indicated on the left (enhancer deletion allele in red). Primers (Ctrl or Ctrl2) amplifying an unrelated genomic region were included as a PCR positive control. See Supplementary Table 3 for all primer sequences and related PCR product sizes. k, Top, Hi-C interaction heat maps of topologically associated chromatin domains (mouse embryonic stem cell TADs) 26 . Bottom, selected enhancers (blue triangles) and their predicted target genes (TSS indicated as black bar). The Capture-C UCSC browser track (purple) illustrates three-dimensional chromatin interaction profiles from E11.5 embryonic limbs (3-kb window) using promoters of the predicted enhancer target genes as anchor points 22 . H3K27ac enrichment (green) in wild-type forelimbs at E11.5 (this study) is shown below. Six of the ten enhancers selected for deletion analysis display local Capture-C enrichment (* ), indicating physical interaction with the predicted target gene promoter at E10.5 or E11.5, based on the stringent statistical approach (95th percentile threshold) applied in the original study 22 . Other genes present in the TAD are shown in grey. Fig. 1a-j) . Shox2-and Sox9-associated LacZ panels are also used in Extended Data Fig. 2. d, Gli3 transcript distribution in situ hybridization in wild-type (Wt) and mm1179/hs1586 DKO embryos. Arrowhead points to reduced Gli3 transcript in the anterior limb mesenchyme. Dashed line indicates dissected hand plate for RNA-seq. e, RNA-seq confirmed significantly reduced Gli3 expression in hand plates of DKO embryos but not individual enhancer knockout embryos (compared to wild-type hand plates). f, Unaffected hindlimb morphology in mm1179/hs1586 DKO embryos. Red arrowhead points to digit 1 duplication in forelimbs (see also Fig. 2 ). g, Shox2 expression (in situ hybridization) in forelimbs and hindlimbs of hs741/hs1262 DKO embryos. The distal-posterior domain (arrowhead) is dependent on hs741 (Extended Data Fig. 2a ). h, Reduced Shox2 expression in forelimbs and hindlimbs of hs741/hs1262 DKO embryos (qPCR). Expression of the nearby Rsrc1 gene was unchanged. i, Left, representative limb skeletons of wild-type and hs741/hs1262 DKO embryos. Hu, humerus; Ul, ulna; Fe, femur; Ti, tibia. Right, mild but significant reduction in humerus ossification length (double arrows) in hs741/hs1262 DKO limb skeletons. * * * P = 1.66 × 10 −7 (two-tailed, unpaired t-test). j, Absence of evident differences in Sox9 expression or skeletal abnormalities in embryos lacking both the hs1467 and mm636 enhancers near Sox9. For in situ hybridization, transcript distribution was reproduced in at least n = 3 independent biological replicates. n represents number of independent biological replicates with similar results. For bar graphs and boxplots, individual biological replicates are shown as data points. Bar graphs illustrate mean and s.d. Box plot indicates median, interquartile values and range. * * * P < 0.001; * * P < 0.01 (two-tailed, unpaired t-test). n.s., not significant. Scale bars, 100 μ m (white) and 500 μ m (black). Corresponding author(s): Diane Dickel, Axel Visel, Len Pennacchio
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Experimental design 1. Sample size
Describe how sample size was determined. Methods, section "Experimental Design" (pages 23 and 24). Specific information related to the different experimental approaches can be obtained in the individual methods sections.
Data exclusions
Describe any data exclusions. Methods, section "Experimental Design" (pages 23 and 24). Specific information related to the different experimental approaches can be obtained in the individual methods sections.
Replication
Describe whether the experimental findings were reliably reproduced.
Attempts at replication were successful and statistical parameters reproducibility numbers are indicated in figure panels/text as required.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Methods, section "Experimental Design" (pages 23 and 24).
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
